Infinity Pharmaceuticals, Inc.
36 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
3
Ending by 2030
Dec 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 16, 2026The maintenance fee for Heterocyclic compounds and uses thereof (US 9,056,877) comes due Dec 16, 2026. Unpaid by Jun 16, 2027, it lapses early.
- 1 fee due Feb 25, 2027The maintenance fee for Substituted Isoquinolinones and Methods of Treatment Thereof (US 9,115,141) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Isoxazolines as inhibitors of fatty acid amide hydrolase (US 9,149,465) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due May 10, 2027The maintenance fee for Chemical compounds, compositions and methods for kinase modulation (US 9,181,221) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Solid Forms of (S)-3-(1-(9H-PURIN-6-Ylamino)ETHYL)-8-Chloro-2-Phenylisoquinolin-1(2H)-ONE and Methods of Use Thereof (US 10,550,122) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Processes for Preparing Isoquinolinones and Solid Forms of Isoquinolinones (US 9,290,497) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Combination therapies (US 11,944,631) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,821,102 | Methods of Use of Cyclopamine Analogs In force · High confidence | In force | High confidence | |
| US 11,602,527 | Methods of Use of Cyclopamine Analogs In force · Low confidence | In force | Low confidence | |
| US 9,879,293 | Enzymatic transamination of cyclopamine analogs In force · From the USPTO record | In force | From the USPTO record | |
| US 9,149,465 | Isoxazolines as inhibitors of fatty acid amide hydrolase In force · From the USPTO record | In force | From the USPTO record | |
| US 9,346,769 | Tetrazolones as inhibitors of fatty acid synthase In force · From the USPTO record | In force | From the USPTO record | |
| US 9,181,221 | Chemical compounds, compositions and methods for kinase modulation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,388,183 | Heterocyclic compounds and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,290,497 | Processes for Preparing Isoquinolinones and Solid Forms of Isoquinolinones In force · High confidence | In force | High confidence | |
| US 9,840,505 | Solid Forms of (S)-3-(1-(9H-PURIN-6-Ylamino)ETHYL)-8-Chloro-2-Phenylisoquinolin-1 (2H)-One and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,550,122 | Solid Forms of (S)-3-(1-(9H-PURIN-6-Ylamino)ETHYL)-8-Chloro-2-Phenylisoquinolin-1(2H)-ONE and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 21: 36 patents in force now held by others · 56 lapsed for an unpaid fee · 3 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 10 abandoned · 26 no status recorded